首页> 外文期刊>BMC Psychiatry >A randomized controlled double-blind clinical trial comparing versus placebo the effect of an edible algal extract (Ulva Lactuca) on the component of depression in healthy volunteers with anhedonia
【24h】

A randomized controlled double-blind clinical trial comparing versus placebo the effect of an edible algal extract (Ulva Lactuca) on the component of depression in healthy volunteers with anhedonia

机译:随机对照双盲临床试验比较了可食用藻类提取物(ULVA Lactuca)对具有Anhedonia健康志愿者抑郁症组成的效果

获取原文
           

摘要

The effects of the seaweed extract were evaluated on the animal model equivalent of depression compared with a control group treated with the carrier (spring water) and a reference group treated with Imipramine and showed significative effect. This clinical trial was intended to confirm in humans the potential efficacy identified in animals. The primary objective was to compare against a placebo the effect of Ulva L.L extract in healthy volunteers whose anhedonia was characterized by a component of depression. Single-centre double-blind randomized placebo-controlled clinical trial on parallel arms of two groups of 45 subjects. The study could include men or women aged 18 to 65?years with anhedonia characterized by a Snaith Hamilton Pleasure Scale score (SHAPS) of ≥5 and feeling low morale for at least four weeks characterized by a component of depression evaluated on the Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR). Evaluation criteria: QIDS-SR; Patient Global Improvement Impression (PGII) and Clinical Global Improvement Impression (CGII). 86 subjects were included in the trial: 42 in the placebo group and 44 Ulva group. At D84, QIDS-SR significantly decreased more in the Ulva.L.L. group than in the placebo group (p: 0.0389). This difference is essentially linked to an improvement of the sleep disorders (p: 0.0219), of the psychomotor consequences (p: 0.002) and of the nutrition behaviour (p: 0.0694). 90.1% have the feeling of being improved in the Ulva group vs 72.5% in the placebo group (p: 0.0114) and in parallel 90.9% of the practitioners have the feeling that the subject has improved vs 70.8% (p: 0.0214). This double-blind randomized placebo-controlled trial shows that daily intake for three months of a water-soluble extract of Ulva L.L. continues to significantly improve the component of depression of subjects presenting anhedonia compared with a placebo. Trial retrospectively registred on ClinicalTrial.gov under ID: NCT03545399 Date: 05/22/2018.
机译:与用载体(弹簧水)处理的对照组相比,对海藻提取物的效果评估了抑郁症的动物模型和用脂氧碱处理的参考组,并显示出有效作用。该临床试验旨在以人类证实动物中鉴定的潜在疗效。主要目标是与安慰剂进行比较,该安慰剂提取物在健康志愿者中的效果,其厌氧志愿者的特征是抑郁症的成分。单中心双盲随机安慰剂控制临床试验两组45个受试者的平行臂。该研究可以包括18至65岁的男性或女性与anhedonia的年龄为特征,其特征是斯娜泰哈米尔顿乐趣比分(Shaps)≥5,并且感觉较低的士气至少四周,其特征在于抑郁症的Quick Inventory的抑郁组成部分抑郁症状学 - 自我报告(QIDS-SR)。评价标准:QIDS-SR;患者全球改善印象(PGII)和临床全球改善印象(CGII)。 86名受试者纳入试验中:42次安慰剂组和44个ULVA集团。在D84,乌尔瓦尔QIDS-SR在Qids-SR中显着降低。小组比安慰剂组(P:0.0389)。这种差异基本上与睡眠障碍(P:0.0219)的改善有关,精神多后果(P:0.002)和营养行为(P:0.0694)。 90.1%在安慰剂组中的ULVA集团与72.5%中有改善的感觉(P:0.0114),并行90.9%的从业者认为受试者改善了70.8%(P:0.0214)。这种双盲随机安慰剂对照试验表明,与安慰剂相比,每日摄入量的ULVA L.L的水溶性提取物的三个月。继续提高呈现Anhedonia的受试者的抑郁症的组分。试用在ClinColicalTrial.gov上注册了ID:NCT03545399日期:05/22/2018。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号